Sign in
CompletedPhase 4

Personalized Dosing of Nicotine Replacement (NRT to Effect)

Key facts

Who runs it
Centre for Addiction and Mental Health
Where
Canada2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
211 people enrolled
Started
23 Jan 2018
Ended
11 Dec 2023
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Nicotine Patch
  • Placebos
Record updated
29 January 2024

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Daily tobacco smoker of ≥10 cigarettes per day
  • Aged 18 to 75 years old
  • Interested in using tNRT as the only smoking cessation aid
  • Intending to quit smoking within the next 30 days

Who cannot take part

  • Currently using or has used NRT or other smoking cessation pharmacotherapy within the past two weeks
  • Any generalized skin disorders precluding the use of the patch
  • Any life threatening arrhythmias or severe/worsening angina pectoris or within two weeks of experiencing a myocardial infarction or cerebral vascular accident
  • Any known hypersensitivity or allergies to any of the components comprising the nicotine patch
  • Current unstable psychiatric condition which would compromise study compliance
  • Diagnosis of terminal illness
  • At least weekly use of tobacco products other than cigarettes and not willing to stop for the duration of the study
  • Breast feeding, pregnancy or not using a reliable form of birth control
  • Current active substance dependence (excluding caffeine) which would compromise study compliance
  • Current regular use of e-cigarettes or other vaping devices containing nicotine and not willing to stop for the duration of the study

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Medications for smoking cessation are currently only effective in helping a minority of smokers quit. Drug development is slow and expensive, so there is much interest in optimizing the effectiveness of existing treatments and medications. Current standard doses of nicotine replacement therapy (NRT) are not effective for many smokers and in many cases provide less nicotine compared to when a smoker is smoking their usual number of cigarettes. The proposed study will test if a personalized dose of nicotine patch (up to 84mg) will improve quitting success in those who do not respond to a standard dose of NRT (21mg).

The 3 groups in the trial

  • Experimental ConditionTreatment being tested

    Participants unable to quit smoking after 2 weeks of treatment with 21mg nicotine patch will get 21mg nicotine patches plus additional active nicotine patches until achieving 7 consecutive days of abstinence over the next 5 weeks; maximum daily patch dose, 84mg/day

    Treatment: Nicotine Patch

  • Placebo ConditionPlacebo, for comparison

    Participant unable to quit smoking after 2 weeks of treatment with 21mg nicotine patch will get 21mg nicotine patches plus placebo patches until 7 consecutive days of abstinence over the next 5 weeks; Maximum daily patch dose, 21mg active nicotine patch plus 3 placebo 21mg patches.

    Treatment: Nicotine Patch and Placebos

  • Quit conditionExisting treatment, for comparison

    Participants able to quit for 7 consecutive days during the first 2 weeks of treatment with 21mg nicotine patch will continue open label 21mg active nicotine patches for the remaining 10 weeks.

    Treatment: Nicotine Patch

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Personalized Dosing of Nicotine Replacement for Smoking Cessation: An Effectiveness Randomized Placebo-controlled Trial
Publications
Record updated
29 January 2024